Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
November 9, 12:11 PM
Clovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on sales of $30.66 million, down from $37.92 million.
FDA Adcomm Backs AstraZeneca’s 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
November 9, 12:04 PM
The FDA’s Pulmonary-Allergy Drugs Advisory Committee has voted 16 to 1 that the data support a favorable benefit-risk assessment for…
Novavax Nuvaxovid Covid-19 Vaccine Authorized In The United Kingdom For Use As A Booster In Adults
November 9, 10:20 AM
Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products
SharpLink Gaming Receives Nasdaq Minimum Bid Price Deficiency Notice
November 9, 9:18 AM
SharpLink Gaming Ltd. (NASDAQ:SBET) ("SharpLink" or the "Company"), "), a pioneer of targeted, data-driven user engagement and conversion solutions for the U.S. sports betting and
Chemomab Presents Clinical Data From Investigator-Initiated Study Showing CM-101 Reduced Inflammatory And Fibrogenesis-Related Biomarkers In Patients With Severe Lung Injury Derived From Covid-19
November 9, 9:12 AM
─New Findings Demonstrate CM-101's Anti-Inflammatory and Anti-Fibrotic Effects Are Highly Relevant to Inflammatory Lung Diseases─
TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
AstraZeneca Announced PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 9, 5:47 AM
The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older.
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
November 8, 3:37 PM
JMP Securities raised the price target to $105 from $90 on Haemonetics Corporation (NYSE:HAE) with a Market Outperform rating following the release of…
Cantor Bullish On Abeona Saying Recent Trial Data ‘Best Case Scenario’
November 8, 3:28 PM
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ:ABEO) from $22 to $40 after adjusting the market model/ increasing the…
Novavax’s Second Booster With Omicron Adapted COVID-19 Shot Shows Encouraging Immune Responses
November 8, 1:33 PM
Novavax Inc (NASDAQ:NVAX) announced topline results from its Phase 3 trial of updated COVID-19 shot against BA.1 strain meeting…